Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs ...

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Associated Therapies: -

Clinical Trials

Heart Rate Reduction in Heart Failure

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: ivabradine
Drug: Carvedilol

First Posted Date: 2010-08-10

Last Posted Date: 2014-09-30

Lead Sponsor: IRCCS San Raffaele

Target Recruit Count: 121

Registration Number: NCT01178528

Locations: 🇮🇹
Centre for Clinical and Basic Research - IRCCS San Raffaele, Roma, Italy
🇮🇹
IRCCS San Raffaele, Roma, Italy

Carvedilol Post-intervention Long-term Administration in Large-scale Trial

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Drug: No Carvedilol
Drug: Carvedilol

First Posted Date: 2010-07-02

Last Posted Date: 2017-06-27

Lead Sponsor: Takeshi Morimoto

Target Recruit Count: 801

Registration Number: NCT01155635

Locations: 🇯🇵
Division of Cardiology, Kyoto University Hospital, Kyoto, Japan

A Trial of Nadolol Plus Isosorbide Mononitrate Versus Carvedilol for the Prevention of Variceal Rebleeding

Phase 4

Completed

Conditions: Variceal Rebleeding

Interventions: Drug: carvedilol
Drug: nadolol + ISMN

First Posted Date: 2010-04-14

Last Posted Date: 2010-10-26

Lead Sponsor: E-DA Hospital

Target Recruit Count: 121

Registration Number: NCT01103154

RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage

Phase 4

Conditions: Portal Hypertension

Interventions: Drug: Carvedilol
Procedure: Esophageal variceal band ligation

First Posted Date: 2010-02-18

Last Posted Date: 2010-02-18

Lead Sponsor: Aga Khan University

Target Recruit Count: 148

Registration Number: NCT01070641

Locations: 🇵🇰
Aga Khan University Hospital, Karachi, Sindh, Pakistan

Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Carvedilol

First Posted Date: 2010-02-08

Last Posted Date: 2010-02-08

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 36

Registration Number: NCT01064154

Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Carvedilol

First Posted Date: 2010-02-08

Last Posted Date: 2010-02-08

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 24

Registration Number: NCT01064180

Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal

Phase 4

Completed

Conditions: Esophageal Varices
Portal Hypertension Gastropathy
Spontaneous Bacterial Peritonitis
Hepatic Encephalopathy
Ascites

Interventions: Drug: placebo
Drug: carvedilol
Drug: propranolol

First Posted Date: 2010-01-29

Last Posted Date: 2017-08-22

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 201

Registration Number: NCT01059396

Locations: 🇪🇸
Hospital Arnau de Vilanova, Lérida, Spain
🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
🇪🇸
Hospital German Trias i Pujol, Badalona, Spain

and more 5 locations

Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Carvedilol

First Posted Date: 2009-08-25

Last Posted Date: 2017-06-08

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 10

Registration Number: NCT00964678

Locations: 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.

Phase 4

Completed

Conditions: Hypoxia
Altitude
Heart Failure

Interventions: Drug: placebo
Drug: Carvedilol
Drug: Nebivolol

First Posted Date: 2009-06-19

Last Posted Date: 2009-09-02

Lead Sponsor: Istituto Auxologico Italiano

Target Recruit Count: 27

Registration Number: NCT00924833

Locations: 🇮🇹
Laboratorio Ricerche Cardiologiche. Istituto Auxologico Italiano. Ospedale S. Luca. Via Spagnoletto, 3. Regina Margherita Hut (Monte Rosa, Italian Alps, 4559 m), Milan, Italy

Mechanisms and Treatment of Intradialytic Hypertension

Phase 4

Completed

Conditions: Intradialytic Hypertension

Interventions: Drug: Carvedilol

First Posted Date: 2009-01-23

Last Posted Date: 2020-11-03

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 55

Registration Number: NCT00827775

Locations: 🇺🇸
UTS Dallas Dialysis (Elmbrook), Dallas, Texas, United States
🇺🇸
UTSW Oakcliff Davita Dialysis, Dallas, Texas, United States
🇺🇸
UTSW Dallas East Davita Dialysis (Buckner unit), Dallas, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy